Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / News/  Cadila, NovaSAID ties up for drug development
BackBack

Cadila, NovaSAID ties up for drug development

Firms will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID

Cadila will bear all costs associated with the program at the laboratory stage.Premium
Cadila will bear all costs associated with the program at the laboratory stage.

Mumbai: Ahmedabad-based Cadila Pharmaceuticals Ltd. and the Swedish drug researcher NovaSAID AB have formed a drug development partnership for new treatments in the area of inflammation and pain management.

The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be conducted at Cadila Pharmaceuticals’ research facility in Ahmedabad, a media statement said on Monday.

As per the agreement, marketing rights on new products in India, the Middle East and Africa will be retained by Cadila and the revenue from sales in all other countries will be shared by the two companies. Cadila, a privately held drugmaker, will bear all costs associated with the program at the laboratory stage.

“We have entered this partnership combining scientific expertise of NovaSAID and our drug development capabilities to work towards novel solutions in treatment of pain and inflammation, which is one of the largest therapy areas," said Rajiv I Modi, chairman and managing director, Cadila Pharmaceuticals, in the statement.

“This partnership gives the shareholders of NovaSAID the opportunity to take the company forward with great resources and no further costs. If successfully developed, valuable deals could be signed in major territories such as the US and Europe to the benefit for Karolinska Development’s shareholders", said Torbjörn Bjerke, chief executive officer of NASDAQ-listed Karolinska Development, the holding company of NovaSAID.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 13 Jan 2014, 09:31 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie